India's Central Drugs Standard Control Organisation (CDSCO) faces criticism for a 74-day delay in disclosing information about an alleged counterfeit rabies vaccine. Doctors and industry experts highlight this as part of a broader pattern of regulatory opacity, citing a lack of disclosure on other quality-related enforcement actions. The delay is concerning given rabies's fatal nature and the critical time window for vaccine efficacy, raising ethical questions about public alerts.